GlassScriptPhysician profile
Michelle Lynn Bigg
NPI 1033781471
$2,700.62
in general payments reported to CMS, 2019-2025
17 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $96.64 · 2023: $465 · 2024: $264 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Long Term Medical Supply Or Device Loan: $897 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.17 |
| Long Term Medical Supply Or Device Loan | $897.30 |
| Education | $186.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,055.58 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $537.35 | 2021-2025 | Tagrisso, Enhertu |
| Daiichi Sankyo INC. | $415.68 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $177.78 | 2021-2022 | |
| Janssen Biotech, INC. | $123.48 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Aveo Pharmaceuticals, INC. | $87.99 | 2024 | |
| Sobi, INC | $37.42 | 2025 | |
| Exelixis INC. | $37.20 | 2021 | |
| Karyopharm Therapeutics INC. | $33.64 | 2023 | Xpovio |
| Celgene Corporation | $32.72 | 2022 | |
| Beone Medicines USA, INC. | $31.81 | 2025 | Brukinsa |
| Pfizer INC. | $27.39 | 2024 | |
| Rigel Pharmaceuticals, INC. | $26.33 | 2021 | |
| Glaxosmithkline, LLC. | $21.72 | 2025 | Jemperli |
| Incyte Corporation | $21.63 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.73 | 2022 | |
| Array Biopharma INC | $14.17 | 2025 | Mektovi, Lorbrena, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.